NEW YORK - Tuesday, 03. December 2024
(BUSINESS WIRE)--The Empire State Building (ESB) today announced details for its fan-favorite holiday festivities with over-the-top decorations, festive pop-ups, classic movie screenings, and special tower lightings.
“There is no place quite like New York to spend the holidays, and the Empire State Building tops the list of things to do in NYC,” said Jean-Yves Ghazi, president of the Empire State Building Observatory. “From photos with Santa to classic film screenings, guests will make holiday memories to last a lifetime with the best views in New York City.”
Topped with Tinsel
Every corner of the Empire State Building Observatory will be adorned in festive holiday decorations with shining wreaths, lights, tinsel, bows, and a giant menorah at the two-story building model. As they make their way through the Observatory Experience’s immersive exhibits, guests can pose for holiday photos in a dedicated corner of the 80th Floor with Christmas trees, snowflakes, presents, and a cozy fireplace backdrop inspired by Santa’s workshop.
Once they reach the iconic 86th Floor Observatory, guests can pose in a dedicated Ghirardelli corner decorated with a candy cane arch, holiday greenery, twinkle lights, and Ghirardelli’s fan-favorite peppermint bark squares.
Guests will conclude their Observatory visit in the building’s famed Fifth Avenue Lobby – featured in the holiday classic, “Elf” – that is decorated with classic holiday decorations like hanging twinkle lights, wreaths, and an oversized Christmas tree. The iconic Fifth Avenue Windows depict scenes of sleighs full of elaborately wrapped gifts, teddy bears, and holiday ice cream sundaes by Ghirardelli Chocolate.
Tenants and visitors who pass through the Fifth Avenue Lobby from Monday through Friday in the month of December will hear holiday tunes performed by professional pianists.
The Man with the Bag
On Nov. 30 and Dec. 7, 9, 11, 14, 16, 18, and 20, Santa Claus himself will spread holiday cheer and pose for photos with Observatory guests in his dedicated corner on the building’s 80th Floor. More information on Santa visits can be found at esbholiday.com.
Baby, It’s Cold Outside
From Nov. 13 throughout the holiday season, Ghirardelli Chocolate will reside on the Empire State Building’s 86th Floor Observatory every day from 10 a.m.-1 p.m. and 5-8 p.m. The beloved chocolatier will offer their classic hot cocoa and peppermint hot cocoa to guests as they take in New York City’s best views from the comfort of the heated open-air Observatory.
Starbucks Reserve® Winter Wonderland
Holiday magic comes alive in the iconic Starbucks Reserve® Empire State Building store with the new, limited-time Winter Wonderland pop-up experience. Located at the Coffee & Cocktail Lounge on the second level of the store, Starbucks Reserve® Winter Wonderland highlights the coffee journey, from bean to cup. Exclusive to the experience is the new Empire State Cocoa Cocktail that features dark chocolate and steamed milk infused with Hennessy VS Cognac, topped with whipped cream, and served with a side of Royal Combier liqueur and dark chocolate bites.
Holiday Classics
Fans can purchase tickets to view classic holiday films on the Observatory’s 80th Floor which include:
“Elf” on Dec. 2, 8, 10, 15, and 17
“Home Alone 2: Lost in New York” on Dec. 5 and 11
And “The Nightmare Before Christmas” on Dec. 13.
Tickets to these special holiday screenings will each include themed drinks and snacks, and full access to ESB’s second floor museum and the 86th and 102nd Floor Observatories.
Special Lightings
The Empire State Building’s iconic tower lights will shine throughout the holiday season with dedicated lightings for Thanksgiving, Chanukah, Christmas, and New Year’s Eve. The building will also debut its annual holiday music-to-light show. Text CONNECT to 274-16 to receive real-time information about each Empire State Building tower lighting.
The Empire State Building’s world-famous Observatory Experience underwent a $165 million reimagination that added a new interactive museum with nine galleries, bespoke host uniforms, and a new 102nd Floor Observatory with unmatched views from the heart of New York City. The iconic Observatory Experience was recently voted the number one attraction in the world – and number one in the U.S. for the third consecutive year – in the 2024 Tripadvisor Travelers’ Choice Awards: Best of the Best Things to Do.
Hi-res imagery can be downloaded here.
More information about the Empire State Building can be found online.
About the Empire State Building
The Empire State Building, the “World's Most Famous Building," owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience created an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building's iconic history to its current place in pop culture. The Empire State Building Observatory Experience welcomes millions of visitors each year and was declared the #1 Attraction in the World – and #1 Attraction in the U.S. for the third consecutive year – in Tripadvisor’s Travelers’ Choice Awards: Best of the Best Things to Do, "America's Favorite Building" by the American Institute of Architects, the world's most popular travel destination by Uber, and the #1 New York City attraction in Lonely Planet’s Ultimate Travel List.
Since 2011, the building has been fully powered by renewable wind electricity, and its many floors house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit esbnyc.com or follow the building's Facebook, X (formerly Twitter), Instagram, Weibo, YouTube, or TikTok.
Source: Empire State Realty Trust, Inc.
Category: Observatory
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202020008/en/
Permalink
https://www.aetoswire.com/en/news/20241202020008r1
Contacts
MEDIA:
Empire State Realty Trust
Jamie Steinberg
212-400-3339
jsteinberg@esrtreit.com
Tuesday, December 3, 2024
Sharjah Marks 53rd UAE Union Day, Celebrates with Global Audience
The emirate of Sharjah today concluded celebrations to mark the 53rd UAE Eid Al Etihad (Union Day), showcasing the country’s vibrant culture and development story. Festivities took place over 13 days, attracting over 250 thousand of UAE nationals, residents, and visitors from around the world, who enjoyed over 200 performances and activities across Sharjah, that included 8 locations around the Emirate of Sharjah, while highlighting the special features of each city around Sharjah. As the celebrations brought together the nation to celebrate together this special occasion, and highlighted the history and the tradition of the United Arab Emirates.
The celebrations included traditional, cultural, and family-friendly activities, ranging from live music performances and folk art displays to interactive workshops and heritage exhibitions. The events culminated in a spectacular series of shows and workshops that were suitable to all ages.
Several exhibitions showcasing the UAE’s achievements, along with workshops for children and families to explore Emirati crafts and traditions, drew a high footfall. Food stalls serving local cuisine, live storytelling sessions, and educational shows provided a festive atmosphere and a rich cultural experience for visitors.
The UAE’s Union Day celebrations were praised this year for their meticulous organization and smooth execution. Events were easy to access and the program was especially diverse, offering entertainment and education for all age groups.
Sharjah’s iconic landmarks were draped with the UAE flag and illuminated in the country’s national colors, adding a festive flair to the occasion.
The celebrations focused on the sense of pride felt by the UAE’s people in the country’s achievements and aspirations, reinforcing Sharjah’s status as a leading cultural hub and a destination of choice for tourists and international events.
Permalink
https://aetoswire.com/en/news/snd03122024en
Contacts
Shady El Gohary
00971551266247
MEPRA Awards 2024: Showcasing Excellence in PR Strategy and Innovation
Dubai, United Arab Emirates - Tuesday, 03. December 2024 AETOSWire Print
Honoring the standout achievements in PR and communications over the past year; the Middle East Public Relations Association (MEPRA) hosted its 16th award edition on November 28, 2024. Attended by over 550 guests, the event gathered 62 top agencies and professionals to contend for esteemed titles across 53 competitive categories, celebrating excellence and transformative impact in the industry.
Showcasing the finest achievements in the industry, the MEPRA Awards 2024 celebrated groundbreaking campaigns, agencies, and professionals who redefined excellence through innovation. With over 770 entries judged by an esteemed panel of 130 industry veterans, the awards spotlighted communication campaigns that excelled in concept, strategy, and impact.
Agencies that outshined the evening for scooping maximum awards had Memac Ogilvy winning 27 titles, Gambit Communications clinching 22 titles and Weber Shandwick securing the third position with 16 awards. The agencies showcased thoughtfully curated campaigns, strategic techniques, and innovative solutions meeting evolving industry needs. The prestigious Chairman’s Award was conferred upon Mr. Jamal Al Mawed (Founder & Managing Director, Gambit Communications) while the Department of Culture and Tourism, Abu Dhabi was pronounced the In-House Team of the Year.
The sector category highlighted the finest of PR and communications success glorifying Dubai Holding’s Gift It Forward Ramadan Campaign 2024 as the Best Business to Business Campaign; while Snap Inc and Weber Shandwick MENAT’s TASAWAR-Taking the Runway won both, Best Fashion Campaign and Best Technology Campaign. Burson took home gold in Best Government Communications and Public Affairs for I Care and Memac Ogilvy and Qatar Foundation co-owned the gold for Best Education Campaign.
The services category of MEPRA Awards 2024 honored ingenuity and commitment to excellence spotlighting Matrix Public Relations for Best Crisis Communication, Gambit Communications and City Centre Mirdif for Best Retail Campaign, and; Weber Shandwick MENAT and Careem Kuwait for Best Consumer Services Campaign. Harnessing the power of digital media, Current Global MENAT and MullenLowe clinched gold for Best Use of Social Media. The winners showcased unmatched resilience in a rapidly evolving communications landscape where expertise demanded adaptability and innovative strategies.
Complimenting the winners, Kate Midttun, Chairperson of MEPRA said; “We have some amazing trailblazers, leaders as well as rising stars of the PR industry tonight as we continue to applaud the efforts channeled towards recognition. Not a single win has been smooth sailing for any of us as agencies continue to strike a winning balance between tighter budgets, deadlines, and client expectations. The emphasis on creative storytelling through owned content and strategic maneuvering of AI and technology to reach newer audiences shows that the Middle East’s PR industry shall continue to reign supreme when it comes to embracing innovation.”
Other notable wins were Current Global MENAT and FP7 for Best Integrated Campaign and Best Use of Media Relations, Brazen MENA for Best Use of Limited Budget, and CYLKA CSR for Best ESG Campaign.
The highlights of the evening were the Large Agency of the Year bagged by Memac Ogilvy followed by Gambit Communications and Matrix Public Relations for Medium Agency of the Year and Small Agency of the Year, respectively. Gambit Communications was crowned as the Homegrown Agency of the Year for a third time, having won this highly coveted award in 2021 and 2022.
Iman Isa of Burson was named the Best Communicator of the Year while Rebecca Rego from Edelman won the Young Communicator of the Year award. Providing a competitive platform to the new generation of PR practitioners, the audience cheered Astha Kurup, Arvy Moga, and Jared Rallos of Murdoch University Dubai for bagging gold in Outstanding Student Campaign.
Weber Shandwick collaborated as Diamond Partner for the third consecutive year with MSL Group Middle East, Action Global Communications, and Memac Ogilvy as Platinum Partners. Supporting partners included CARMA, Edelman, Mubadala, TECOM Group Dubai, SEC Newgate Middle East, TrailRunner International, Burson, AMEC Measurement and Evaluation, Place Communications, LPME Studios, Matrix PR, and First and Ten Productions.
About MEPRA:
The Middle East Public Relations Association (MEPRA) is the leading industry body for the public relations and communications industry in the Middle East. MEPRA has more than 1,000 members, which include consultancies, corporates with in-house public relations functions, and individual industry professionals. The organisation was founded in 2001 and is headquartered in the United Arab Emirates. MEPRA drives growth and sets standards of excellence in regional public relations. It is the unique voice for the industry and aims to nurture the development of public relations professionals.
For more information visit www.mepra.org
Permalink
https://www.aetoswire.com/en/news/mepra03122024e
Contacts
Ambika Jadeja, Account Manager
Jr. Account Manager, Matrix Public Relations
ambika@matrixdubai.com
04-343088
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
OSAKA, Japan & CAMBRIDGE, Mass. - Tuesday, 03. December 2024
− Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and myelofibrosis
− Takeda to receive exclusive global license in all territories outside of mainland China, Hong Kong and Macau
− Transaction builds upon Takeda’s legacy in the treatment of hematologic cancers and advances company’s global oncology strategy
(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau.
Elritercept is a late-stage investigational activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes (MDS) and myelofibrosis (MF). The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of elritercept for very low-, low- and intermediate-risk MDS. MDS and MF are characterized by inadequate blood cell production, often leading to severe anemia that significantly impacts patient health and quality of life. Elritercept targets activin A and B proteins, which are believed to play a crucial role in anemia-associated diseases. In early clinical studies, elritercept has shown promising clinical activity and a manageable safety profile in patients with very low-, low- and intermediate-risk MDS as a monotherapy and in patients with MF in combination with standard of care.
“Elritercept has the potential to make a meaningful difference for patients with blood cancers, one of our key areas of strategic focus,” said Teresa Bitetti, President of the Global Oncology Business Unit at Takeda. “The addition of elritercept further bolsters our oncology pipeline and introduces a potential future growth driver for Takeda. I am excited to further advance the pioneering work begun by the Keros Therapeutics team with the goal of delivering this potential treatment option to patients.”
Elritercept is currently in two ongoing Phase 2 clinical trials; one in patients with very low-, low- or intermediate-risk MDS and one in patients with MF. The Phase 3 RENEW trial evaluating elritercept in adult patients with transfusion-dependent anemia with very low-, low- or intermediate-risk MDS will begin enrollment soon. Takeda plans to evaluate elritercept in these cancers across patient segments and lines of therapy.
“We are excited to partner with Takeda, whose global reach and expertise in oncology and hematology will help unlock elritercept’s potential for patients with MDS and MF,” said Jasbir S. Seehra, Ph.D., Chair and Chief Executive Officer at Keros Therapeutics. “With a differentiated mechanism of action targeting a broad range of pathways in blood cell production, elritercept has shown promise for patients who have not responded to standard therapies. This collaboration will accelerate development of elritercept for patients in need and offer new insights into these complex hematologic conditions.”
Under the terms of the agreement, Takeda will receive an exclusive worldwide license to further develop, manufacture and commercialize elritercept in all indications and territories outside of mainland China, Hong Kong and Macau. Takeda will be responsible for all development, manufacturing and commercialization as of the effective date of the agreement. Takeda will provide Keros Therapeutics with an upfront payment of $200 million and potential payments relating to regulatory, development and commercial sales milestones, as well as royalties on net sales. The agreement is subject to customary closing conditions, including completion of antitrust reviews.
About Myelodysplastic Syndromes (MDS)
Myelodysplastic syndromes (MDS) are a group of diverse blood cancers in which the bone marrow fails to produce enough healthy blood cells. MDS is among the most common hematologic malignancies, with approximately 20,000 new cases diagnosed annually in the United States.1 Most people with MDS experience anemia, or low red blood cell counts, which impacts quality of life and mortality.2 75% of people living with MDS have low-risk MDS, with a median survival of approximately three to 10 years.3,4 Many low-risk MDS patients require frequent red blood cell transfusions, which can increase over time and negatively impact quality of life.5 Despite advances, additional therapeutic options are needed to improve quality of life and anemia symptoms for patients with low-risk MDS, particularly those whose disease is ringed sideroblast-negative or who have a high transfusion need.
About Myelofibrosis (MF)
Myelofibrosis (MF) is a rare and life-threatening blood cancer characterized by the buildup of scar tissue in the bone marrow, which impairs its ability to produce normal blood cells. In the United States, approximately 3,000 new cases of MF are diagnosed each year.6 Patients with MF often experience anemia, enlarged spleen and other symptoms that significantly affect their quality of life. Although standard treatments can reduce spleen size and improve symptoms, they may exacerbate anemia and lead to low platelet counts.
About Elritercept
Elritercept is an investigational, potentially best-in-class activin inhibitor, targeting both activin A and activin B proteins, which are believed to play a crucial role in anemia-associated diseases. Elritercept is currently in two ongoing Phase 2 clinical trials; one in patients with very low-, low- or intermediate-risk MDS and one in patients with MF. The Phase 3 RENEW trial evaluating elritercept in adult patients with transfusion-dependent anemia with very low-, low- or intermediate-risk MDS will begin enrollment soon. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of elritercept for this condition.
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
References:
Gorak E, et al. Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies. Blood Adv. 2023 Oct 24;7(20):6120-6129. doi: 10.1182/bloodadvances.2023010061.
Haring Y, et al. MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level. J Clin Med. 2023 Sep 9;12(18):5865. doi: 10.3390/jcm12185865.
de Witte T, et al. Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome: The European LeukemiaNet MDS Registry and MDS-RIGHT project perspective. Haematologica. 2020 Nov 1;105(11):2516-2523. doi: 10.3324/haematol.2020.266817.
Sekeres M, et al. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review. JAMA. 2022 Sep 6;328(9):872-880. doi: 10.1001/jama.2022.14578.
Wood E, et al. Outpatient transfusions for myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):167-174. doi: 10.1182/hematology.2020000103.
Mehta J, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014 Mar;55(3):595-600. doi: 10.3109/10428194.2013.813500. Epub 2013 Jul 29.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202182459/en/
Permalink
https://www.aetoswire.com/en/news/20241202182459r1en
Contacts
Media:
Japanese Media
Tsuyoshi Tada
tsuyoshi.tada@takeda.com
U.S. and International Media
Jennifer Anderson
jennifer.anderson@takeda.com
KnowBe4’s Artificial Intelligence Defense Agents To Combat AI-Generated Phishing Attacks and Measure Cyber Risk in Humans
TAMPA BAY, Fla. - Monday, 02. December 2024
KnowBe4’s new Artificial Intelligence Defense Agents (AIDA) to advance human risk management
(BUSINESS WIRE)--KnowBe4, the world-renowned cybersecurity platform that comprehensively addresses human risk management, today announced a new innovative suite of AI-native security agents designed to automate and enhance human risk management – AIDA.
AIDA is a suite of agents that enhances the approach to human risk management by leveraging multiple AI technologies to create personalized, adaptive and highly effective training for all end users that actually changes behavior. Underpinning the entire suite of agents is the SmartRisk AgentTM. SmartRisk Agent leverages end user behavioral data from across KnowBe4's products to help measure cyber risk in humans. This agent’s multidimensional Risk Scores are designed to make it easier for security professionals to see potential problems at the user, group and organizational levels.
According to a LastPass 2024 survey, over 95% of cybersecurity professionals believe AI-generated content makes phishing detection more challenging. This technological advancement in the hands of bad actors has created a new breed of highly convincing social engineering attacks that one-size-fits-all security awareness training struggles to combat.
“AIDA is not merely the next step in KnowBe4's human risk management, it is a quantum leap forward,” said Stu Sjouwerman, CEO, KnowBe4. “It offers a suite of AI-native agents that transform how security professionals approach human risk management. AIDA empowers organizations to stay ahead of AI-based cybersecurity attacks by measuring human risk scores to better understand and mitigate threats within the risk landscape.”
The first four agents that have been released include:
Automated Training Agent: Uses AI with 316 indicators influencing 37 factors across 7 knowledge areas to analyze end users’ learning history, job role, risk score, behavior patterns and even languages so AIDA can automatically assign the most relevant and engaging content.
Template Generation Agent: Leveraging generative AI, AIDA creates highly realistic phishing templates that can mirror current attack vectors. Social Engineering Indicators, or red flags, are based upon the NIST Phish Scale Framework.
Knowledge Refresher Agent: AIDA delivers bite-sized knowledge refreshers at optimal intervals, ensuring end users actually apply critical security concepts.
Policy Quiz Agent: AIDA generates intelligent quizzes based on an organization's specific security and compliance policies.
AIDA is available as an add-on for KnowBe4 customers with a Diamond level KnowBe4 subscription. For more information on AIDA, visit https://www.knowbe4.com/products/AIDA.
About KnowBe4
KnowBe4 empowers workforces to make smarter security decisions every day. Trusted by over 70,000 organizations worldwide, KnowBe4 helps to strengthen security culture and manage human risk. KnowBe4 offers a comprehensive AI-driven ‘best-of-suite’ platform for Human Risk Management, creating an adaptive defense layer that fortifies user behavior against the latest cybersecurity threats. The HRM+ platform includes modules for awareness & compliance training, cloud email security, real-time coaching, crowdsourced anti-phishing, AI Defense Agents, and more. As the only global security platform of its kind, KnowBe4 utilizes personalized and relevant cybersecurity protection content, tools and techniques to mobilize workforces to transform from the largest attack surface to an organization’s biggest asset.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202080117/en/
Permalink
https://www.aetoswire.com/en/news/E54158996
Contacts
For more information please contact Kathy Wattman at pr@knowbe4.com | 727-474-9950.
Nurse Maria Victoria Juan from Philippines wins the prestigious Aster Guardians Global Nursing Award 2024
Dubai, United Arab Emirates
Nurse Maria Victoria Juan from Philippines, a Consultant at Philippines Army Health Services and Colonel, Reserve Force of the Armed Forces of the Philippines, has been announced as the winner of Aster Guardians Global Nursing Award 2024 and awarded with USD 250,000 at a prestigious award ceremony held in Bengaluru, India.
Launched in 2021, the Aster Guardians Global Nursing Award recognizes the critical role of nurses in healthcare. This year, over 78,000 applications were received from 202 countries, marking a 50% increase from 2023. Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, delivered a special message commending the finalists and acknowledging Aster DM Healthcare's efforts in highlighting the importance of nurses.
Nurse Maria said, “As a military nurse from the Philippines, my journey has been defined by a steadfast commitment to service—whether caring in combat zones, disaster-stricken areas, or underserved communities, and championing advocacies on every platform to create positive change. This recognition reflects not just my efforts, but also the courage and honor of the soldiers I proudly serve alongside and the resilience of the Filipino people that inspire me daily.
It is also a tribute to the nurses I represent—tireless, selfless, extremely courageous individuals in the military and civilian sectors who put themselves in harm's way to save lives and protect others.”
Dr. Azad Moopen, Founder Chaiman, Aster DM Healthcare stated, “Maria exemplifies nursing excellence and is an inspiration to the global healthcare community. Nurses are the backbone of healthcare, offering care with compassion and playing a pivotal role in the system. The Aster Guardians Global Nursing Awards honor these unsung heroes and their invaluable contributions.”
Alisha Moopen, Managing Director and Group CEO, Aster DM Healthcare added, “Maria Juan embodies the courage, skill, and compassion that elevate healthcare. Through this platform, we aim to bring their remarkable stories to the forefront.”
About Aster DM Healthcare:
Founded in 1987 by Dr. Azad Moopen, Aster DM Healthcare is a leading integrated healthcare provider, with a strong presence across seven countries. Aster is committed to the vision of providing accessible and high-quality healthcare, from primary to quaternary services, with its promise of “We will treat you well”.
Permalink
https://www.aetoswire.com/en/news/ag02122024en
Contacts
Lavanya Mandal
Head of PR and Internal Communications
Aster DM Healthcare GCC
+971528126577
lavanya.mandal@asterdmhealthcare.com
Monday, December 2, 2024
IHS Towers Signs Agreement to Sell Kuwait Operations to Zain Group
LONDON & KUWAIT CITY -
(BUSINESS WIRE)--IHS Holding Limited, (NYSE: IHS) (“IHS Towers”), one of the largest independent owners, operators and developers of shared communications infrastructure in the world by tower count, has signed a definitive agreement to sell IHS Towers’ 70% interest in IHS Kuwait Limited (“IHS Kuwait”) including its approximate 1,675 sites and an additional approximately 700 sites managed in Kuwait to Zain Group. The transaction is subject to customary closing conditions, including government and regulatory approvals, and is expected to close in the first half of 2025.
The terms of the transaction reflect an enterprise value1 of $230 million for the IHS Kuwait portfolio, implying a transaction multiple of 14.2x based on an estimated IHS Kuwait Adjusted EBITDA after leases2. This represents a significant premium compared to the current valuation multiple of the IHS Towers group.
Entering into this agreement is part of IHS Towers' ongoing strategic review targeted at shareholder value-creation options. As previously indicated, the proceeds will primarily be utilized to reduce company debt.
Sam Darwish, Chairman & CEO, IHS Towers, commented, “Today’s announcement forms part of our wider ambition to drive shareholder value and enhance our balance sheet. The transfer of IHS Kuwait to Zain, the largest mobile network operator in Kuwait, not only highlights the significant value contained within our portfolio but will also allow us to further reduce our net leverage.”
About IHS Towers: IHS Towers is one of the largest independent owners, operators and developers of shared communications infrastructure in the world by tower count and is solely focused on the emerging markets. The Company has over 40,000 towers across its 10 markets, including Brazil, Cameroon, Colombia, Côte d’Ivoire, Egypt, Kuwait, Nigeria, Rwanda, South Africa and Zambia. For more information, please email: communications@ihstowers.com or visit: www.ihstowers.com
About Zain Group: Zain is a leading telecommunications operator across the Middle East and Africa, serving 47.2 million active customers as of 30 September 2024. With a commercial presence in 8 countries, Zain provides mobile voice and data services in: Kuwait, Bahrain, Iraq, Jordan, Saudi Arabia, Sudan and South Sudan. In UAE, ZainTECH, the Group’s one-stop digital and ICT solutions provider, is playing a key role in the transformation of enterprise and government clientele across the MENA region. Also, UAE based, Zain Omantel International (ZOI) is revolutionizing the international telecommunications wholesale landscape as the premier wholesale powerhouse serving regional operators, international carriers, and global hyper scalers. In Morocco, Zain has a 15.5% stake in ‘INWI’, through a joint venture. Zain is listed on the Boursa Kuwait (stock ticker: ZAIN). For more, please email info@zain.com or visit: www.zain.com
Cautionary Language Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates," “believes,” “estimates,” “forecast,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. You should read this press release and the documents that we reference in this press release with the understanding that our actual future results, performance and achievements may be materially different from what we expect. Further information on such assumptions, risks and uncertainties is available in our filings with the US Securities and Exchange Commission, including our Annual Report on Form 20-F for the fiscal year ended December 31, 2023. We qualify all of our forward-looking statements by these cautionary statements. These forward-looking statements speak only as of the date of this press release. Except as required by applicable law, we do not assume, and expressly disclaim, any obligation to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events or otherwise.
Certain definitions
We define Adjusted EBITDA by segment as income/(loss) for the period, before income tax expense/(benefit), finance costs and income, depreciation and amortization, impairment of withholding tax receivables, impairment of goodwill, business combination transaction costs, impairment of property, plant and equipment, intangible assets excluding goodwill and related prepaid land rent, reversal of provision for decommissioning costs, net (gain)/loss on sale of assets, share-based payment (credit)/expense, insurance claims and certain other items that management believes are not indicative of the core performance of our business.
1 Enterprise value is defined as anticipated cash consideration to be received plus borrowings less cash in the business and stated for a 100% shareholding.
2 Estimated Adjusted EBITDA for the MENA segment for the year ended December 31, 2024, excluding non-Kuwait segment costs of $0.4 million, and reduced by $12 million for incremental lease costs in Kuwait.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241127457326/en/
Permalink
https://www.aetoswire.com/en/news/20241127457326r1
Contacts
communications@ihstowers.com
www.ihstowers.com
The LYCRA Company Previews Bio-Derived LYCRA® EcoMade Fiber at ISPO
WILMINGTON, Del. - Monday, 02. December 2024 AETOSWire
(BUSINESS WIRE)--The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the apparel industry, announced today that it is promoting its bio-derived LYCRA® EcoMade fiber at ISPO, December 3 to 5. The company is showcasing samples featuring the renewable elastane in Hall A3, Stand 101, and offering visitors a fully immersive VR experience to learn about the product. It will also be featured in the Sustainability Hub (Hall A2) and is the subject of a presentation.
Bio-derived LYCRA® EcoMade fiber won two ISPO Textrends Awards for Fall/Winter 2026/27. In the fibers and insulation category, this renewable elastane won a “Top 5 Award,” and a garment made with the same fabric was recognized as a “Selection” in the pants & tights category. The Brazilian activewear and swimwear brand LIVE! produced the fabric and leggings using preview samples of this highly anticipated fiber.
Launching in 2025, bio-derived LYCRA® EcoMade fiber will be the world’s first large-scale commercially available renewable elastane. The award-winning product previewed at ISPO contains 70 percent renewable content and is certified under the USDA Bio-Preferred Program. The fiber delivers equivalent performance to the original LYCRA® fiber, and no re-engineering of fabrics, processes, or garment patterns is required.
“We believe bio-derived LYCRA® EcoMade fiber represents an exciting future where we can make real, transformative change in the industry without sacrificing performance,” said Steve Stewart, The LYCRA Company’s chief brand and innovation officer. “We are thrilled to receive this recognition from ISPO and applaud our customer LIVE! for creating the award-winning fabric and garment.”
The LIVE! brand is renowned for its high-quality, sustainable apparel, and its UpFit Capsule Collection includes the ISPO award-winning leggings, Bermuda-length leggings, a top, and a jumpsuit. These garments made with bio-derived LYCRA® EcoMade fiber provide exceptional comfort, fit, and flexibility with the added benefit of being a more sustainable fiber.
“At LIVE!, we believe the future of fashion must balance innovation with environmental responsibility,” said Joice Sens, founder and creative director at LIVE!. “This collection embodies the spirit of LIVE! FUTURE, our sustainable innovation lab, and highlights the importance of partnerships like this one with the LYCRA® brand, enabling us to develop products that combine cutting-edge technology with reduced impact."
Steve Stewart is presenting “All In: The Power of Partnership” on ISPO’s Green Stage on December 4 at 16:00 CET. His presentation details how collaboration has been critical to commercializing bio-derived LYCRA® EcoMade fiber and bringing it to market.
Visit The LYCRA Company’s ISPO Event Page for show information and to discover the range of sustainable solutions fueling its exhibit: COOLMAX® and THERMOLITE® EcoMade fibers made from textile waste, and LYCRA® FiT400™ fiber designed for circularity, are made with the planet in mind. To learn more about bio-derived LYCRA® EcoMade fiber, visit this webpage for product information.
About The LYCRA Company
The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers’ products by offering unique innovations that meet the consumer’s need for comfort and lasting performance. Learn more at lycra.com.
LYCRA®, COOLMAX® and THERMOLITE® are trademarks of The LYCRA Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202374744/en/
Permalink
https://www.aetoswire.com/en/news/20241202374744r1
Contacts
Izaskun Hernanz
izaskun.hernanz@lycra.com
Raxio Group, Africa's Most Expansive Data Centre Network, Appoints Robert Skjødt as CEO
AMSTERDAM - Monday, 02. December 2024 AETOSWire
Skjødt brings more than 30 years of experience, with a career that spans leadership roles in major energy, renewables and infrastructure firms worldwide. For the last decade he focused on Africa, where he led the creation of BTE, a pan-African renewable energy company, which was acquired by global energy giant Engie in 2023. Skjødt previously held senior positions at ABB, a global leader in power and automation technologies, where he oversaw complex infrastructure projects and M&A activity across multiple continents.
With a network of state-of-the-art Tier III carrier-neutral data centres in Uganda, Ethiopia, Mozambique, the Democratic Republic of Congo, Côte d'Ivoire, Tanzania and Angola, Raxio is uniquely positioned to meet the growing demand for reliable digital infrastructure in Africa's emerging economies. Under Skjødt's leadership, the company plans to enter additional high-growth markets while increasing its capacity in existing markets to support digital transformation on the continent.
"Our goal is to accelerate Africa's digital growth responsibly," said Robert Skjødt. "By combining Raxio's expertise in data centre development with sustainable energy practices, we can provide essential infrastructure that not only meets the needs of today but also preserves resources for future generations. I'm excited to lead Raxio in expanding our reach and deepening our commitment to environmental stewardship."
Frans Van Schaik, Chairman of Raxio Group, highlighted the strategic significance of Skjødt's appointment. "Robert's proven track record in pioneering infrastructure projects across Africa aligns perfectly with Raxio's vision for growth. His leadership will be pivotal as we scale our operations and enhance our services to meet the evolving needs of our clients," he said.
Raxio's expansion strategy focuses on underserved markets with significant growth potential, and is ideally positioned to respond to growing continental and global needs for data centre capacity while minimising electricity and water usage for power and cooling. By 2027, Raxio plans to establish data centres in at least five additional African countries, more than doubling current capacity and solidifying its position as the continent's leading data centre network. This ambitious growth plan is underpinned by Raxio’s unique track-record of building best-in-class data centres and an uncompromising commitment to customer service, safety and sustainability.
Skjødt, who will join Jan. 1, was appointed following a comprehensive search conducted by executive firm Egon Zehnder, reflecting Raxio's dedication to strategic leadership and continuity. The outgoing CEO, Robert Mullins, transformed Raxio from a single-project venture into a multi-country operation, and will remain an advisor to ensure a seamless transition.
"When we started, our mission was to build one data centre in Uganda," said Mullins. "Today, Raxio stands as the only operator with a presence in seven African countries. I am confident that under Robert Skjødt's leadership, the company will not only expand its footprint and capacity but also set new standards for sustainability and operational excellence in the industry."
Raxio Group's unique approach bridges the digital divide by providing high-quality, reliable infrastructure in markets often overlooked by larger operators. This strategy fosters local economic development and innovation by enabling businesses and institutions to access world-class data centre services.
"As we look to the future, our focus remains on delivering impactful infrastructure that empowers African economic leadership," said Van Schaik. "With Robert Skjødt at the helm, Raxio is poised to lead the way in sustainable data centre development, ensuring that our growth benefits both our clients and the communities we serve."
About Raxio Group
Raxio Group is Africa’s premier provider of Tier III carrier-neutral colocation data centres, offering reliable and scalable infrastructure to support the continent's digital transformation. With facilities in Uganda, Ethiopia, Mozambique, the Democratic Republic of Congo, Côte d'Ivoire, Tanzania, and Angola, Raxio delivers high-quality services that enable businesses and institutions to thrive in the digital age. Committed to sustainability and innovation, Raxio empowers economic growth across Africa.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202715516/en/
Permalink
https://www.aetoswire.com/en/news/20241202715516r1
Contacts
Gavin Serkin
gserkin@frontierintelligence.org
+44 7767 252489
South Korean Chungbuk National University to Install First Quantum Computer IQM Spark
CHEONGJU, South Korea - Monday, 02. December 2024 AETOSWire
This is the first full-stack quantum computer to be installed at the Chungbuk National University campus.
The university will use the system to drive quantum research and education programming.
IQM will deliver and install the system in the first quarter of 2025. This will also be the first quantum computer from IQM in South Korea, and second in the APAC region.
(BUSINESS WIRE)--Chungbuk National University (CBNU) today announces the purchase of its first quantum computer from IQM Quantum Computers (IQM), a global leader in designing, building, and selling superconducting quantum computers, aimed at driving quantum research and education programming while preparing students for the quantum workforce.
The recent adoption of the quantum computer marks a significant milestone as the first commercial quantum computer to be installed through the Korean government’s official procurement process.
The Chungbuk Quantum Research Center (CBQRC) in CBNU, established with support from the Chungbuk Provincial Government, has been instrumental in facilitating this initiative. Professor Kiwoong Kim, Director of the CBQRC, stated, “We hope that the introduction of this quantum computer will serve as a catalyst for accelerating quantum technology exchange and industrialization between Finland and Korea.”
The installation of the 5-qubit full-stack quantum computer named “IQM Spark” will begin in the first quarter of 2025. This announcement reflects Chungbuk National University and IQM’s shared commitment to support South Korean’s government efforts to promote quantum education and training.
The quantum computer to be deployed at the university’s campus is part of IQM’s global fleet of machines accessible through the cloud and on-site and delivered to customers in the US, France, Germany, Finland, among others.
“Having our on-site first quantum computer in South Korea and second in the APAC region is a significant achievement for us and has several benefits for Chungbuk National University,” said Dr. Mikko Välimäki, Co-CEO at IQM Quantum Computers. “Our system will give the university flexibility and control, while also providing students with practical experience in quantum computing.”
About IQM Quantum Computers:
IQM is a global leader in designing, building, and selling superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its computers anywhere in the world. IQM customers include the leading high-performance computing centres, research labs, universities and enterprises which have full access to IQM's software and hardware. IQM has over 280 employees with offices in Espoo, Madrid, Munich, Paris, Palo Alto, Singapore and Warsaw.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202186804/en/
Permalink
https://www.aetoswire.com/en/news/20241202186804r1
Contacts
Email: press@meetiqm.com
Mobile: +358504790845
www.meetiqm.com
Bureau Veritas completes the acquisition of The APP Group, strengthening its Buildings & Infrastructure leadership position in Asia-Pacific
(BUSINESS WIRE)--Bureau Veritas, a global leader in Testing, Inspection, and Certification services, today announced that it has completed the acquisition of The APP Group, a leading Australian Property and Infrastructure leader, as stated in its communication to the market on November 4th, 2024. The company is headquartered in Sydney and delivered revenues of €87 million in 2023.
This acquisition is in line with Bureau Veritas’ LEAP | 28 strategy to expand leadership in Buildings and Infrastructure, diversifying its portfolio and investing in an attractive regional market. It will strengthen the Group’s Buildings and Infrastructure capabilities by adding significant project management assistance expertise to asset owners, as well as construction management, independent project verification and certification and benefiting from a leverageable regional scale.
“I am delighted to welcome our new colleagues from The APP Group. This is a major step forward in the execution of our LEAP | 28 strategy. The combined expertise of Bureau Veritas and The APP Group is not only strengthening our position in the Australian market but also providing us with a robust and sustainable platform to support B&I services growth in the wider Asia Pacific region,” said Hinda Gharbi, Chief Executive Officer of Bureau Veritas. “Bringing a team of more than 500 employees and access to a pool of over 200 specialist sub-consultants, the integration of The APP Group now establishes our position as a partner of choice to government, infrastructure owners, large corporations and private companies.”
About Bureau Veritas
Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress.
With a vision to be the preferred partner for its customers’ excellence and sustainability, the company innovates to help them navigate change.
Created in 1828, Bureau Veritas’ 83,000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.
Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40 ESG, CAC Next 20, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit www.bureauveritas.com, and follow us on LinkedIn.
About The APP Group
The APP Group is a leader in Australian Property and Infrastructure, as a trusted partner, working together with clients and key stakeholders to create possibilities and shape progress for the organizations themselves and the communities they serve. Operating an integrated services model across the full asset capital investment lifecycle in the key sectors: Transport, Property, Social Infrastructure, Modern Methods of Construction, Energy & Utilities and Defense & Security.
The APP Group team provide market leading service solutions, expertise and advice to help tackle Australia’s most complex projects and challenges, backed by a 500 plus-strong nationwide team.
For more information, visit www.app.com.au
Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241201814044/en/
Permalink
https://www.aetoswire.com/en/news/54159613
Contacts
ANALYST/INVESTOR CONTACTS
Laurent Brunelle
+33 (0)1 55 24 76 09
laurent.brunelle@bureauveritas.com
Colin Verbrugghe
+33 (0)1 55 24 77 80
colin.verbrugghe@bureauveritas.com
Karine Ansart
+33 (0)1 55 24 76 19
karine.ansart@bureauveritas.com
MEDIA CONTACTS
Anette Rey
+33 (0)6 69 79 84 88
anette.rey@bureauveritas.com
Martin Bovo
+33 (0) 6 14 46 79 94
martin.bovo@bureauveritas.com
GE HealthCare to Acquire Remaining 50% Stake in Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan, from Sumitomo Chemical
GE HealthCare to acquire 50% stake from Sumitomo Chemical to assume full ownership of NMP, subject to regulatory approvals
As part of GE HealthCare, NMP, already a leading radiopharmaceutical company in Japan, will enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease
Acquisition positions NMP to become partner of choice for global innovators looking to bring novel radiopharmaceuticals to Japan and other Asian markets
Transaction bolsters GE HealthCare’s Pharmaceutical Diagnostics segment and demonstrates its commitment to shaping the future of Molecular Imaging
(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing from Sumitomo Chemical (TYO: 4005) the 50% stake it does not already own. As part of GE HealthCare, NMP can build on its expertise developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease. Sumitomo and GE HealthCare expect the agreement to close in early 2025, subject to regulatory approvals.
NMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable clinical images across neurology, cardiology and oncology procedures, such as its amyloid visualization radiotracer, VIZAMYL® Injection (Flutemetamol (18F) Injection), used in the Alzheimer’s pathway; DaTSCAN® Injection (Ioflupane (¹²³I) injection) used to evaluate patients with suspected Parkinson’s Disease or Dementia with Lewy Bodies; and MYOVIEW® (Technetium (99mTc) Tetrofosmin), used in SPECT myocardial perfusion imaging for the evaluation of known or suspected coronary artery disease. NMP, headquartered in Tokyo, was formed in 1973 and generated revenues of 28.2B JPY (~$183M) in 2023. In addition to 13 manufacturing facilities, NMP also focuses on research and development, including nonclinical and clinical development of radiotracers and theranostics research. GE HealthCare has held its 50% stake in NMP since acquiring Amersham plc in 2004 and holds three positions on its Board of Directors.
Kevin O’Neill, President & CEO of the Pharmaceutical Diagnostics (PDx) segment of GE HealthCare, said: “As the third largest pharmaceutical market in the world1, and amongst the leading countries by number of cyclotrons2, Japan is on a path to becoming a leader in the $7 billion molecular imaging global market and a center of excellence for Asian markets. NMP will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring novel products to the Japan market and beyond. This will strengthen our precision care strategy in Asia and our existing footprint in Japan, where our contrast media and medical devices are used every day to enable imaging procedures across the country.”
Hiroshi Ueda, Executive Vise President, Sumitomo Chemical, said: “We are proud of our 50-year relationship with NMP and our partnership with GE HealthCare to ensure patients in Japan could benefit from access to molecular imaging. At a time of exciting developments in the industry, following its discussions with Sumitomo Chemical, we believe GE HealthCare is the best owner to enable NMP to continue its successful growth journey. I would like to recognize NMP’s leadership and talented team for their significant achievements to date and their commitment to patients.”
As a leading global medical technology and pharmaceutical diagnostics innovator, GE HealthCare provides both molecular imaging equipment and proprietary radiotracers used across major patient care areas. The recent U.S. FDA approval of GE HealthCare’s first-of-its-kind PET radiopharmaceutical, Flyrcado™ (flurpiridaz F 18 injection), its in-licensing of Phase II FAPI assets and broadening theranostics offerings are all examples of the company’s commitment to novel diagnostics that are shaping the future of molecular imaging to drive improved patient outcomes. GE HealthCare’s PDx segment is a global leader in imaging agents used to support over 120 million patient procedures per year globally, equivalent to four patient procedures every second.
The Company expects this transaction to be neutral to Adjusted EPS3,4 in year one and accretive thereafter.
GE HealthCare was advised by Solomon Partners Securities, LLC.
Forward-Looking Statements
This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” “forecast,” “target,” “guidance,” “outlook,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the completion and expected results of the transaction, and GE HealthCare Technologies Inc.’s (the “Company’s”) performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the conditions to the completion of the transaction may not be satisfied; closing of the transaction may not occur or may be delayed; the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; the Company may assume unexpected risks and liabilities; and completing the transaction may distract the Company’s management from other important matters. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.
1 https://www.trade.gov/country-commercial-guides/japan-pharmaceuticals, accessed on October 29, 2024
2 https://nucleus.iaea.org/sites/accelerators/Pages/Cyclotron.aspx, accessed on October 29, 2024
3 See our latest earnings release dated October 30, 2024 for the definition of Adjusted EPS.
4 Non-GAAP financial measure
View source version on businesswire.com: https://www.businesswire.com/news/home/20241201060498/en/
Permalink
https://www.aetoswire.com/en/news/20241201060498r1
Contacts
GE HealthCare Media Contact:
David Morris
M +44 7920 591370
david.j.morris@gehealthcare.com
Mathilde Bouscaillou
M +33 647 008271
mathilde.bouscaillou@gehealthcare.com
NetApp Announces Integrated Solution with AWS Outposts for Hybrid Cloud Deployments
SAN JOSE, Calif. - Monday, 02. December 2024
New integration simplifies the use of NetApp block storage with AWS Outposts
(BUSINESS WIRE)--NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced NetApp on-premises enterprise storage arrays for AWS Outposts, a new integrated solution allowing AWS Outposts customers to simplify the use of external block data volumes running on NetApp on-premises enterprise storage arrays in AWS Outposts deployments directly through the Amazon Web Services (AWS) Management Console. AWS Outposts is a family of fully managed solutions delivering AWS infrastructure and services to virtually any on-premises or edge location for a truly consistent hybrid experience. This solution simplifies hybrid cloud deployments by combining NetApp’s unified data storage and intelligent services with powerful cloud infrastructure offered by AWS Outposts, helping customers optimize cloud deployments on-premises and at the edge.
“Whether customers are looking to use hybrid cloud infrastructure to increase resiliency or improve compliance, leveraging NetApp storage in AWS Outposts can help customers run applications securely and efficiently at the edge,” said Jonsi Stefansson, Senior Vice President and Chief Technology Officer at NetApp. “This solution makes it simpler for customers to leverage NetApp intelligent data infrastructure to manage their data in AWS Outposts deployments. By automating volume attachments, IT teams can now tap into the efficiency and power of NetApp on-premises storage arrays to power critical workloads.”
Customers with Outpost servers or racks can now use the AWS Management Console to simplify the use of external block data volumes for enterprise applications and database workloads running on Outposts and NetApp on-premises enterprise storage arrays. Customer benefits include:
Simplified User Experience: With this solution, customers can attach block data volumes backed by NetApp on-premises enterprise storage arrays to Amazon Elastic Compute Cloud (Amazon EC2) instances on Outposts directly from the AWS Management Console. This simplifies the user experience by automating volume attachments.
Resilient and Optimized Infrastructure: The solution allows customers to use the capabilities of NetApp’s intelligent data infrastructure such as NetApp SnapMirror® and NetApp Snapshot™ while tapping into the storage efficiencies in Outpost deployments for a resilient, compliant, and optimized infrastructure.
Seamless Hybrid Cloud: By leveraging NetApp’s unified approach to data storage, AWS Outposts users will have a seamless and certified hybrid cloud experience that uses industry-leading tools and services to manage and protect their data in Outposts deployments, AWS Local Zones deployments using Cloud Volumes ONTAP®, the rest of their own data centers, and the cloud when using services such as Amazon FSx for NetApp ONTAP.
Additionally, Spot by NetApp is releasing new capabilities for its automated infrastructure optimization solution for containers and Kubernetes, Spot Ocean. As organizations scale their cloud Kubernetes operations to meet increasing application workload demands, they need a solution that helps them optimize their infrastructure while controlling costs. The new capabilities in Spot Ocean help organizations achieve those goals with a new fast-response auto-scaler that ensures clusters have the infrastructure to meet workload requirements, a dynamic commitment utilization process that uses available resources before provisioning on-demand or preemptive instances, and a new dashboard that provides more visibility and insights into cost optimization efforts and infrastructure efficiency.
To explore these new capabilities and learn how NetApp can enhance your AWS environment, visit the NetApp booth #1748 at AWS re:Invent in Las Vegas from December 2-6, 2024.
Additional Resources
AWS Outposts
NetApp Storage Integration with AWS Outposts
Continuous Infrastructure Optimization—A Cornerstone to a Successful FinOps Strategy
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241201494379/en/
Permalink
https://www.aetoswire.com/en/news/54159611
Contacts
Media Contact:
Kenya Hayes
NetApp
kenya.hayes@netapp.com
Investor Contact:
Kris Newton
NetApp
kris.newton@netapp.com
Subscribe to:
Posts (Atom)